Acute myeloid leukemia: open trials in Sweden

21 open trials have a site in Sweden. Registry data; only the trial team decides who can take part.

NCT07223814
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Trial Treatment · Phase 3 · Stichting Hemato-Oncologie voor Volwassenen Nederland
Sahlgrenska University Hospital-Vaestra Goetalandsregionen, Goteborg · Karolinska University Hospital, Huddinge · Region Skane Skanes Universitetssjukhus, Lund · Uppsala University Hospital, Uppsala
Registry updated 2026-11-06
2024-512753-24-00
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
Trial Treatment · Phase 3 · Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Sahlgrenska University Hospital-Vaestra Goetalandsregionen, Goteborg · Karolinska University Hospital, Huddinge · Region Skane Skanes Universitetssjukhus, Lund · Uppsala University Hospital, Uppsala
Registry updated 2026-10-21
NCT03934372
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Trial Treatment · Phase 1/2 · Incyte Biosciences International Sàrl
Karolinska University Hospital, Solna, Stockholm
Registry updated 2026-10-09
2023-504999-25-00
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML)
Trial Treatment · Phase 3 · Prinses Maxima Centrum voor Kinderoncologie B.V.
Queen Silvia Childrens Hospital - Sahlgrenska University Hospital - Vastra Gotalandsregionen, Gothenburg · Region Oestergoetland, Linkoping · Region Skane Skanes Universitetssjukhus, Lund · Karolinska University Hospital, Solna · Region Vaesterbotten, Umea · Uppsala University Hospital, Uppsala
Registry updated 2026-09-23
NCT06652438
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Trial Treatment · Phase 3 · Stichting Hemato-Oncologie voor Volwassenen Nederland
Sahlgrenska University Hospital-Vaestra Goetalandsregionen, Goteborg · Karolinska University Hospital, Huddinge · Region Skane Skanes Universitetssjukhus, Lund · Uppsala University Hospital, Uppsala
Registry updated 2026-09-02
NCT07766850
Addition of Hydroxyurea to Fludarabine, Cytarabine, Idarubicin and Venetoclax Salvage Therapy for Adults With Relapsed or Refractory Acute Myeloid Leukemia
Trial Treatment · Phase 1/2 · Christer C Nilsson
Medical Unit Hematology, Karolinska University Hospital, Stockholm
Registry updated 2026-08-17
2025-521390-14-00
Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)
Trial Treatment · Phase 2 · Pediatric Research International GmbH
Queen Silvia Childrens Hospital - Sahlgrenska University Hospital - Vaestra Goetalandsregionen, Gothenburg
Registry updated 2026-08-04
2026-526961-76-00
FLAsH-IV-AML: A study evaluating the safety and effectiveness of adding hydroxyurea to treatment for adults with acute myeloid leukemia (AML) that has relapsed after treatment or has not responded to treatment
Trial Treatment · Phase 1/2 · Karolinska University Hospital
Sahlgrenska University Hospital-Vaestra Goetalandsregionen, Goteborg · Karolinska University Hospital, Huddinge · Region Oerebro Laen, Orebro · Uppsala University Hospital, Uppsala
Registry updated 2026-07-14
NCT04068597
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Trial Treatment · Phase 1/2 · CellCentric Ltd.
Karolinska Comprehensive Cancer Center, Stockholm
Registry updated 2026-06-24
NCT06281847
An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia
Trial Treatment · Phase 1/2 · Advesya SAS
Karolinska University Hospital, Stockholm
Registry updated 2025-09-18
NCT03850574
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Trial Treatment · Phase 1/2 · Aptose Biosciences Inc.
Karolinska University Hospital, Huddinge
Registry updated 2025-08-26
NCT07075016
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Trial Treatment · Phase 3 · Stichting Hemato-Oncologie voor Volwassenen Nederland
SE-Goteborg-SAHLGRENSKA, Gothenburg · SE-Lund-SUH, Lund · SE-Stockholm-KAROLINSKAHUDDINGE, Stockholm · SE-Uppsala-UPPSALAUH, Uppsala
Registry updated 2025-08-19
NCT06262438
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
Trial Treatment · Phase 2 · Princess Maxima Center for Pediatric Oncology
Queen Silvia Childrens Hospital - Sahlgrenska University Hospital - Vaestra Goetalandsregionen, Gothenburg · Region Oestergoetland, Linkoping · Region Skane Skanes Universitetssjukhus, Lund · Karolinska University Hospital, Solna · Region Vaesterbotten, Umea · Uppsala University Hospital, Uppsala
Registry updated 2025-08-05
NCT06793410
Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation
Trial Treatment · Phase 2 · Vastra Gotaland Region
Sahlgrenska University Hospital, Gothenburg · Linkoping University Hospital, Linköping · Skåne's University Hospital, Lund · Karolinska University Hospital, Stockholm · Uppsala University Hospital, Uppsala
Registry updated 2025-06-05
NCT05477589
Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML
Trial Treatment · Phase 3 · Vastra Gotaland Region
Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Gothenburg · Barncancercentrum, avdelning 64, Skane University Hospital, Lund · Pediatric Hematology immunology and stem cell transplantation Astrid Lindgren children's Hospital Huddinge K86-88, Stockholm · Childrens department for Blood and tumor diseases Uppsala University Hospital, Uppsala
Registry updated 2024-12-19
NCT01828489
NOPHO-DBH AML 2012 Protocol: Research study for treatment of children and adolescents with acute myeloid leukemia 0-18 years
Trial Treatment · Phase 3 · Vaestra Goetalandsregionen
Queen Silvia Childrens Hospital - Sahlgrenska University Hospital - Vaestra Goetalandsregionen, Gothenburg · Region Oestergoetland, Linkoping · Region Skane Skanes Universitetssjukhus, Lund · Karolinska University Hospital, Solna · Region Vaesterbotten, Umea · Uppsala University Hospital, Uppsala
Registry updated 2024-11-22
2023-506865-71-00
An adaptive open-label multicentre phase 1/2 trial, to determine the recommended phase 2 dose of CCTx-001, and to assess safety, tolerability, and clinical activity in patients with relapsed/refractory acute myeloid leukaemia (RESOLVE AML 001)
Trial Treatment · Phase 1/2 · CanCell Therapeutics
Karolinska University Hospital, Huddinge
Registry updated 2024-09-27
NCT03999723
Combining Active and Passive DNA Hypomethylation
Trial Treatment · Phase 2 · Kirsten Grønbæk
Sahlgrenska University Hospital, Gothenburg · Skåne University Hospital, Lund · Karolinska University Hospital, Stockholm · Uppsala University Hospital, Uppsala
Registry updated 2024-04-17
NCT04793919
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
Trial Treatment · Phase 2 · Associazione Italiana Ematologia Oncologia Pediatrica
Queen Silvia Childrens Hospital - Sahlgrenska University Hospital - Vaestra Goetalandsregionen, Gothenburg · Region Oestergoetland, Linkoping · Region Skane Skanes Universitetssjukhus, Lund · Karolinska University Hospital, Solna · Region Vaesterbotten, Umea · Uppsala University Hospital, Uppsala
Registry updated 2024-04-15
NCT05788679
A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS
Trial Treatment · Phase 2 · Karolinska University Hospital
Department of Hematology, Karolinska University Hospital, Stockholm
Registry updated 2023-12-05
NCT05431257
Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling
Trial Treatment · Phase 2 · Copenhagen University Hospital, Rigshospitalet
Karolinska University Hospital, Huddinge · Lund University Hospital, Lund · Region Oerebro Laen, Orebro · Uppsala University Hospital, Uppsala
Registry updated 2022-06-24

All Acute myeloid leukemia trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error